Chapter 4 - subject m-13
Police obtained an emergency warrant for the Aureline offices and the home Melissa shared with Brian.
Mara remained at the hospital, receiving updates while Melissa underwent repeated blood tests.
The search of Aureline found no official pregnancy study.
Its approved work involved mineral supplements and laboratory models, not human subjects.
The company’s public research files contained no reference to AR-7 or Lumen-4.
A hidden directory on Brian’s computer did.
The folder was named M-13.
Melissa’s full name never appeared.
Only measurements.
Weight.
Blood pressure.
Hormone levels.
Fetal heart rate.
Reported fatigue.
Frequency of dizziness.
Response after dosage.
Dr. Richardson read the entries from a printed copy.
Week 14: first injection accepted without suspicion.
Week 19: increased oral dosage.
Week 27: maternal concerns neutralized through reassurance.
Week 32: external testing canceled.
Week 37: placental response visible.
Week 38: final induction trigger.
Melissa stopped reading.
“Induction?”
Dr. Richardson looked at the blood results.
“The silver capsule may have contained something designed to alter your body’s response near labor.”
“Is that why the bleeding started?”
“Possibly. We are still identifying it.”
A second document described the intended outcome:
Live birth following controlled placental stress.
Collection of maternal blood, cord blood, placenta, and neonatal response data.
The protocol did not mention protecting the mother.
It discussed maintaining viability long enough to collect samples.
Melissa pressed one hand over her mouth.
She had spent the pregnancy believing Brian monitored every meal because he loved her.
He had been measuring her.
Mara sat beside the bed.
“The search team found a locked cabinet in your garage.”
“What was inside?”
“Capsule molds, supplement labels, injection vials, and a digital scale.”
Brian had manufactured each dose at home.
No laboratory assistant had helped.
No hidden research network was required.
He designed the compounds at Aureline, carried small quantities out, and prepared them privately.
“Why?” Melissa whispered.
Mara showed her an investor letter.
Aureline had been losing money for eighteen months. Its primary prenatal product failed to attract a buyer because the company lacked evidence supporting its most ambitious claims.
Brian promised investors that he possessed human data demonstrating controlled placental adaptation.
The acquisition deadline was the following morning.
If he delivered complete data from a live birth, Aureline would receive a seventy-million-dollar purchase offer.
Melissa looked toward the fetal monitor.
“He used our daughter to sell his company.”
“And you,” Mara said.
Another document revealed a second motive.
Brian had taken out a five-million-dollar life-insurance policy on Melissa after the first injections began. The policy classified pregnancy complications as natural medical events unless criminal conduct was established.
If Melissa and the baby survived, he gained the data.
If Melissa died, he gained money and an explanation.
The protocol’s risk section stated:
Maternal loss would not invalidate fetal-tissue findings if samples are preserved within ninety minutes.
Dr. Richardson removed the page from Melissa’s sight.
She had already seen enough.
Outside the room, Brian’s attorney announced that his client denied poisoning anyone. He claimed Melissa consented to a private self-directed study and that Dr. Richardson had caused unnecessary panic.
Brian was not yet under arrest.
The consent documents created enough uncertainty for investigators to continue building the case.
A temporary order barred him from the ward and from contacting Melissa directly.
He sent a message through his attorney.
The silver capsule was necessary. Abrupt intervention may endanger the fetus. Let me explain the dosing schedule to her doctors.
Dr. Richardson responded through police.
Provide the complete compound formulas and all dosing records.
Brian refused unless he was allowed to supervise treatment.
“He wants access,” Melissa said.
“He wants control,” Mara replied.
The hospital laboratory identified the silver capsule’s primary effect.
It did not induce ordinary labor.
It temporarily increased stress within the placenta while suppressing contractions, creating a narrow window in which blood and tissue markers would peak before delivery.
Brian wanted Melissa transported to EverVale during that window.
He planned to collect the exact data investors demanded.
Then Mara received photographs from the garage cabinet.
One vial carried a handwritten label:
Post-delivery phase.
May you like
It was empty.
👉 Brian’s experiment was not supposed to end when Melissa gave birth—he had already administered something intended to act afterward.
